EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Infusion Reactions to Infliximab in Pediatric Patients with Inflammatory Bowel Disease

Rajmohan Dharmaraj iD, Tess Pei Lemon, Rasha Elmaoued, Ricardo Orlando Castillo, Razan Alkhouri

Children · 10.11.2024 · 11 (11) · 1366

DOI: 10.3390/children11111366 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Children, online erschienen am 10.11.2024. Verfasst von Rajmohan Dharmaraj und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infliximab (IFX) is a recombinant DNA-derived chimeric IgG monoclonal antibody protein that inhibits tumor necrosis factor alpha (TNF-α). IFX, like other agents derived from foreign proteins, can cause infusion reactions both during and after the infusion. The incidence of infusion reactions ranges between 0% and 15% in pediatric patients. The potential underlying mechanisms for these reactions may include anaphylaxis and anaphylactoid reactions, cytokine release syndrome, serum sickness-like reactions, and the development of antibodies against IFX. Several precautions can help reduce the risk of a new infusion reaction, such as a gradual increase in the infusion rate, scheduled infusions, and administering premedication or immunomodulators alongside IFX. Acute mild to moderate reactions often resolve spontaneously after a temporary cessation of the infusion or reduction in the infusion rate. Strategies like graded dose challenges and premedication can be utilized to prevent recurrence. In cases of severe reactions, desensitization or switching to an alternative biologic may be considered. This article aims to review the most recent guidelines for managing IFX-related infusion reactions in pediatric patients with inflammatory bowel disease (IBD), relying on the best available evidence.

Schlagwörter

Stichwörter der Autor:innen

childreninfiximabinfusion reactionmanagementprevention

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA.

ORCID-Profile: Rajmohan Dharmaraj

Zitieren

APA

Dharmaraj, R., Lemon, T. P., Elmaoued, R., Castillo, R. O., & Alkhouri, R. (2024). Infusion Reactions to Infliximab in Pediatric Patients with Inflammatory Bowel Disease. Children, 11(11), 1366. https://doi.org/10.3390/children11111366

Vancouver

Dharmaraj R, Lemon TP, Elmaoued R, Castillo RO, Alkhouri R. Infusion Reactions to Infliximab in Pediatric Patients with Inflammatory Bowel Disease. Children. 2024;11(11):1366. doi:10.3390/children11111366

BibTeX
@article{Dharmaraj2024,
  author = {Dharmaraj, Rajmohan and Lemon, Tess Pei and Elmaoued, Rasha and Castillo, Ricardo Orlando and Alkhouri, Razan},
  title = {Infusion Reactions to Infliximab in Pediatric Patients with Inflammatory Bowel Disease},
  journal = {Children},
  year = {2024},
  volume = {11},
  number = {11},
  pages = {1366},
  doi = {10.3390/children11111366}
}
Kostenlos starten →